Title:
THERAPEUTIC AGENT TARGETING RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULAR TARGET THERAPEUTIC DRUGS
Document Type and Number:
Japanese Patent JP2022180377
Kind Code:
A
Abstract:
To provide molecular target therapeutic drugs via receptor proteins.SOLUTION: Tumor growth can be inhibited by molecular target therapeutic drugs such as an antibody medicine or a nucleic acid medicine targeting NPTXR. Since they are novel molecular targets, the cases on which the existing therapeutic drugs have no effect can be treated.SELECTED DRAWING: Figure 11
Inventors:
Mitsuro Kanda
Application Number:
JP2022134818A
Publication Date:
December 06, 2022
Filing Date:
August 26, 2022
Export Citation:
Assignee:
Immunobio AG
International Classes:
A61K45/00; A61K31/7088; A61K31/7105; A61K31/711; A61K39/395; A61K48/00; A61P35/00; C07K16/28; C12N15/113; C12N15/115; C12Q1/02; C12Q1/686; C12Q1/6876; G01N33/15; G01N33/50; G01N33/53
Attorney, Agent or Firm:
SK Patent Attorney Corporation
Akihiko Okuno
Hiroyuki Ito
Akihiko Okuno
Hiroyuki Ito
Previous Patent: Electrolyte containing 6-membered cyclic sulfate
Next Patent: Buffer rubber and its reaction force adjustment method and pedestal
Next Patent: Buffer rubber and its reaction force adjustment method and pedestal